Annual Congress on Rare Diseases and Orphan Drugs

Rare Disease is a branch of medicine which is an important public health issue and challenge for the medical community. They are called “Health Orphan”. The term “Orphan Drug” refers to a drug or biologics such as vaccine or blood product that treats a rare disease or conditions. Rare Diseases-2016 will be the best platform for all the specialists and super specialists, renowned Scientists, research scholars, students who are working in this field across the globe under a single roof to exchange their knowledge related to Rare Diseases and Orphan Drugs. This international event is an effort to find an alternative for invasive imaging technique against diseases like rare infectious diseases, rare cancer, Morgellons, Renal cell carcinoma, malignant glioma, Multiple myeloma, Hepatocellular carcinoma etc.

“Annual Congress on Rare Diseases and Orphan Drugs” is going to be held on 26-27 Oct, 2016 at Chicago, Illinois, USA. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We look forward to having you be part of the event!

Rare Diseases-2016 is going to held in Chicago, a city in the U.S. state of Illinois, is the third most populous city in the United States and the most populous city in the American Midwest, with approximately 2.7 million residents. Its metropolitan area (also called “Chicago land”), which extends into Indiana and Wisconsin, is the third-largest in the United States, after those of New York City and Los Angeles, with an estimated 9.8 million people. Chicago is the county seat of Cook County, though a small portion of the city limits also extends into Du Page County.

There are approximately 7,000 rare diseases, which from a regulatory perspective are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. “Orphan drugs” are medicinal products intended for diagnosis, prevention or treatment of life-threatening or debilitating rare diseases. They are “orphans” because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions.

Leave a Reply

Your email address will not be published. Required fields are marked *